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Multidrug resistance resulting from a variety of defensive pathways in cancer 
has become a global concern with a considerable impact on the mortality 
associated with the failure of traditional chemotherapy. Therefore, further 
research and new therapies are required to overcome this challenge. In 
this work, a cyclic R10 peptide (cR10) is conjugated to polyglycerol-covered 
nanographene oxide to engineer a nanoplatform for the surmounting 
of multidrug resistance. The nuclear translocation of the nanoplatform, 
facilitated by cR10 peptide, and subsequently, a laser-triggered release of 
the loaded doxorubicin result in efficient anticancer activity confirmed by 
both in vitro and in vivo experiments. The synthesized nanoplatform with a 
combination of different features, including active nucleus-targeting, high-
loading capacity, controlled release of cargo, and photothermal property, 
provides a new strategy for circumventing multidrug resistant cancers.
many graphene-based antitumor systems 
have been constructed and much pro-
gress has been achieved in this field, the 
situation becomes more complicated and 
challenging when it meets the multidrug 
resistance (MDR).[14,15] The emergence of 
MDR is largely owing to the overexpres-
sion of ATP-binding cassette, in particular, 
P-glycoprotein (P-gP), on the plasma 
membrane.[14–16] These proteins reduce 
the internalization of therapeutic agents 
into the cells and even mediate the efflux 
of these agents from the cells. In recent 
years, a variety of functional nanomaterials 
and smart nanodevices were developed to 
incapacitate P-gP and to deliver anticancer 
drugs across the plasma membrane.[16,17] 
Despite the efficient cellular uptake and 
improved drug concentration inside the cytoplasm of cancer 
cells, the “efflux pump” still frustrates the chemotherapy.[14–16] 
This shortage is more serious when it comes to therapeutic 
agents with specific targeting organelles, such as doxorubicin 
(DOX), whose anticancer mechanism is to intercalate with DNA 
in the nucleus.[18,19] Therefore, efficient tumor therapy could 
hardly be achieved if MDR is not efficiently suppressed and ther-
apeutic agents are not localized into the target organelles.[18,19]
Recently, nucleus-targeting strategies were proposed for the 
chemotherapy of MDR tumors by DOX.[20] By this strategy, DOX 
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1. Introduction
Cancer-related death, which is one of the most terrible killers 
around the world, will rise to around 150 million by 2020.[1] 
The development of safer and more effective tumor treatment 
tactics is urgent but still formidable.[2,3] Graphene, as the most 
widely used 2D nanomaterials, has shown extraordinary perfor-
mance in the antitumor nanomedicine exploitation,[4–6] which 
is attributed to its stability, photothermal property, high loading 
capacity, fast cellular uptake, and biodegradability.[7–13] Although 
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could be delivered into nucleus and the “efflux pump” on the 
plasma membrane could be hopefully avoided. Arginine-rich 
cell-penetrating peptides (CPPs), particularly the TAT peptide, 
which originates from the HIV-1 virus, are shown to be efficient 
vectors to translocate nanoparticles including mesoporous 
silica nanoparticles,[21,22] upconversion nanoparticles,[23] copper 
sulfide nanoparticles,[24] and polymer nanoparticles[25,26] into 
the cell nucleus. Cyclization of CPPs has been demonstrated 
as a new strategy to improve their ability as transmembrane 
carriers and nucleus targeting agents.[27–31] For example, cyclic 
TAT (cTAT) has been proven to show higher ability to facili-
tate the cellular translocation of proteins than linear TAT at 
4  °C.[30] The interna lized cTAT-decorated protein is distributed 
both in the cytoplasm and in the nucleolus, a nuclear compart-
ment.[30] Moreover, cyclic R10 peptide (cR10) even has displayed 
higher transduction location efficacy than cTAT.[32] Accordingly, 
cR10 peptide is supposed to be an effective molecule for the 
nuclear targeting and translocation of nanocarriers into cells.[32]
Furthermore, the size of nanoparticles restricts their ability to 
enter the cellular nucleus.[33,34] In general, nanoparticles bigger 
than 40  nm can scarcely cross the nuclear membrane.[20,33,34] 
Graphite could be exfoliated to small sheets, 15–30  nm, via 
intensified oxidation processes.[35,36] The obtained nanogra-
phene oxide (nGO) contains a large number of epoxy and 
hydroxyl functional groups on the basal plane and carboxyl 
on its edges.[36] Moreover, hyperbranched polyglycerol (hPG) 
with great potential in a wide range of biomedical applications, 
including drug delivery, tissue engineering, and pathogen inter-
actions,[37,38] has been used to improve the biological safety and 
performances of nanomaterials, such as graphene.[39–41]
In this work, we have synthesized polyglycerol-function-
alized nGO derivatives with the ability of the intra-nucleus 
delivery and release of antitumor therapeutic agents and MDR 
suppression (Figure 1). nGO with a 15–30 nm average size was 
produced and functionalized by hPG via an amidation reac-
tion. Subsequently, cR10 peptide was conjugated to the residual 
amino groups of hPG and DOX was loaded onto the nGO 
sheets by noncovalent interactions. While hPG and cR10 peptide 
improved the biocompatibility and nuclear internalization of 
nGO sheets, respectively, laser irradiation triggered the intra-
nucleus release of DOX from the carrier. Both in vitro and in 
vivo results have demonstrated the successful overcoming of 
the MDR and improved antitumor effect of the loaded DOX.
2. Results and Discussion
2.1. Synthesis of the cR10-Functionalized Polyglycerol-Covered 
Nanosheets
nGO was produced according to the reported procedure 
in literature.[35] hPG with 10% amino functional groups 
(hPG(NH2)10%) was prepared via an azido substitution and 
reduction procedure from hPG.[15] Then, the hPG(NH2)10% was 
conjugated onto nGO via an amidation reaction with 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC.
HCl) as condensing agent in 2-(N-morpholino)ethanesulfonic 
acid solution (MES) to obtain hPG-covered nGO (GOP).[15] 
Afterward, (bicyclo[6.1.0]non-4-yn-9-yl)methyl 4-nitrophenyl 
carbonate (BCN) was applied to modify GOP with cyclooctyne 
moieties to produce GOPBCN.[42] The reaction between thiol 
group of cR10 peptide and cyclooctyne moieties of GOPBCN in 
PBS resulted in nanoplatforms with the peptide functionality 
(GOPR) (Scheme  1).[43] Detailed information about the syn-
thesis and characterizations of GOPR can be found in the Sup-
porting Information.
TEM images showed the average size of nGO was around 
17  nm (Figure  2A), while the value slightly increased after 
covering by hPG and conjugation of peptides (Figure 2B,C). 
The small average size (20  nm) is a significant factor that 
can affect the cellular uptake and nucleus localization of 
GOPR.
The composition of nGO, GOP, and GOPR was investigated 
by X-ray photoelectron spectroscopy (XPS), UV-vis absorp-
tion, and thermogravimetric analysis (TGA). In Figure 2D, the 
C1s component peak at 284.6 eV is assigned to sp² hybridized 
Figure 1. Suppression of MDR by polyglycerol-covered nGO sheets. After efficient uptake by the tumor cells, nanosheets localize inside the nucleus by 
cR10 peptide. Consequently, an intra-nucleus release of DOX triggered by NIR irradiation resulted in efficient chemophototherapy against MDR tumors.
Adv. Funct. Mater. 2020, 30, 2000933
www.afm-journal.dewww.advancedsciencenews.com
2000933 (3 of 10) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Scheme 1. Synthesis routes for the production of nGO, GOP, and GOPR. Detailed information for step i, ii, iii, and iv are as follow: i) dispersed 
in mixture (v/v = 3:1) of H2SO4 (98%) and HNO3 (65%), 120 °C, 2 d; ii) with hPG(NH2)10%, dispersed in MES solution including EDC.HCl, room 
temperature (RT), overnight; iii) with BCN, dispersed in dimethylformamide (DMF) including triethylamine (TEA), RT, overnight; iv) with cR10 peptide, 
dispersed in PBS (7.4), RT, overnight.
Figure 2. The TEM images and size profiles of A) nGO, B) GOP, and C) GOPR nanomaterials. The scale bars correspond to 200 nm. The highly resolved 
C1s XPS spectrum of D) nGO, E) GOP, and F) GOPR nanomaterials.
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carbon bonds of the graphene platform. Component peaks at 
286.2 and 288.1  eV were attributed to CO and C=O bonds 
created after oxidation of graphite. This result confirmed the 
disruption of the plane and edges of graphene and formation 
of a large number of carbonyl, hydroxyl, carboxyl, and epoxy 
functional groups upon oxidation (Figure 2D). C1s XPS spectra 
of GOP and GOPR showed successful stepwise conjugation 
of hPG and cR10 peptide to the nGO. (Figure  2E,F, Table S1, 
Supporting Information). The appearance of CN bond related 
component peaks in the survey spectra of GOP and GOPR 
were attributed to the amino groups, amide groups, and guani-
dine groups in hPG(NH2)10% and cR10. In order to confirm the 
reaction between the thiol group of cR10 and GOPBCN, a control 
reaction was performed. Accordingly, cR10 without thiol func-
tional group was incubated with GOPBCN and the product of 
the reaction was characterized by XPS. Significant changes in 
the XPS spectrum of the product were not found, which indi-
cated that peptide was not conjugated to the graphene sheets 
(Table S2, Figures S1 and S2, Supporting Information). This 
control reaction proved the critical role of thiol group for the 
conjugation of cR10 to GOPBCN.
The composition of the synthesized nanomaterials, as well 
as their peptide contents, were further investigated by UV–vis 
experiments. They showed a characteristic absorption peak at 
225  nm, which was used to determine the concentration of 
nGO in the aqueous solutions (Figure S3A, Supporting Infor-
mation). According to these UV–vis experiments, the nGO and 
hPG contents of GOP were around 46% and 54%, respectively. 
After conjugation of cR10 peptide to GOP, the nGO decreased 
to around 43.8%, indicating around 4.8% peptide content for 
GOPR (Figure S3B, Supporting Information). Data related to 
the composition of nanomaterials can be found in Supporting 
Information, page 9.
2.2. Cellular Uptake and Intracellular Distribution
The characterized materials were used for the cell experi-
ments, including cytotoxicity and intra-nucleus localization. 
According to Cell Counting Kit-8 (CCK-8) assays, the tox-
icity of GOP and GOPR against multidrug-resistant HeLa 
(HeLa-R) cells was negligible up to 300 µg mL−1 (Figure S5, 
Supporting Information). The low toxicity of these nanoma-
terials holds promise for biomedical applications. Therefore, 
we labeled the nanomaterials by fluorescein isothiocyanate 
(FITC) (Figure S6, Supporting Information) and investigated 
their uptake by HeLa-R cells using confocal laser scanning 
microscopy (CLSM) (Figure  3A,B) and fluorescence-activated 
cell sorting (FACS) (Figure  3C). GOP showed very low cel-
lular uptake after 6 h incubation due to the hPG coverage.[40] 
However, GOPR was efficiently taken up by HeLa-R cells, 
indicating a significant role for cR10 in the cellular internali-
zation of functionalized nanosheets (Figure  3B). The quan-
titative data obtained by FACS showed an increase in the 
Figure 3. The CLSM images of living HeLa-R cells incubated with A) FITC-labeled GOP (GOPF) and B) FITC-labeled GOPR (GOPRF) for 1, 3, and 6 h, 
respectively. Scale bars correspond to 50 µm. C) FACS results for HeLa-R cells after 6 h incubation with GOPF and GOPRF. HeLa-R cells without any 
treatments were applied as a control. D) CLSM-based statistical analysis of the nucleus translocation efficacy for the HeLa-R cells incubated with GOPF 
and GOPRF for 1, 3, and 6 h. Mean ± SD. (n = 3, Student’s t-test, *p < 0.0001).
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uptake efficiency ten times after conjugation of cR10 peptide to 
nanosheets (Figure 3C).
It has been shown that conjugation with cyclic cell-penetrating 
peptides (cCPPs) like cR10 or cTAT enhanced the transduction 
of protein-cargo in living cells.[30,32] Additionally, non-cleavable 
cCPP conjugates have shown the ability to accumulate in the 
nucleoli within the nucleus.[32] Along these lines, we proposed 
that the conjugation of cR10 peptide to nanomaterials is effective 
for the nuclear localization of their cargos. Interestingly, the intra-
nucleus translocation of GOPR was very efficient and cR10 was 
able to facilitate the localization of nanosheets inside the nucleus 
(Figure 3B). Statistical analysis was applied to calculate the per-
cent of the cells with nucleus-translocated graphene sheets 
(Figure 3D). While localization of GOP into the nucleus of cells 
after 6 h incubation was negligible, GOPR was effectively trans-
ferred into the nucleus and around 80% of cells affected by the 
nucleus-targeting peptide.
2.3. Preparation of DOX-Loaded Nanosheets and Their  
Release Profiles
The action site of DOX is inside of the nucleus, where it 
inhibits the macromolecular biosynthesis of DNA and causes 
apoptosis of carcinoma cells.[18,19] Therefore, translocation 
of this therapeutic agent inside the nucleus, after cellular 
internalization, is a crucial step. However, many nanocarriers 
discharge DOX molecules in the cytoplasm, which causes 
failure of chemotherapy against MDR cells.[14,16,17]
cR10 peptides with the ability of driving the nanosized gra-
phene sheets into nucleus are supposed to facilitate the locali-
zation of their cargo, DOX molecules, inside this compartment. 
DOX-loaded GOP and GOPR (GOPD and GOPRD, respectively) 
were prepared according to reported methods.[44] The loading 
capacities of GOPD and GOPRD were calculated to be 12.5% 
(w/w%) and 11.7% (w/w%), respectively. The lower loading 
capacity of GOPD and GOPRD, in comparison with the reduced 
GO derivatives, was assigned to the disrupted graphene basal 
plan and limited sites for the efficient hydrophobic and π-π 
interactions with DOX molecules.[44] However, the loading 
capacity was still higher than most of the polymer-based 
nanocarriers.[45]
The photothermal effect is an unique characteristic for the 
graphene-based nanomaterials,[8,46] which is also beneficial 
for the controlled release of their cargo.[47,48] GOP and GOPR 
solutions at different concentrations were irradiated with the 
near-infrared (NIR) laser and the temperature variations were 
recorded (Figure S7, Supporting Information). After 10 min irra-
diation, the temperature of the aqueous solutions of GOP and 
GOPR (1 mg mL−1) increased to 50 °C, which was enough for 
triggering the release of their cargo as well as an efficient photo-
thermal therapy.[8,15] The ability of laser irradiation to accelerate 
the release of DOX from GOPD and GOPRD was investigated at 
pH 5.6 and 7.4 (Figure 4). As expected, the release rate increased 
upon NIR laser irradiation, which was ascribed to the increased 
temperature of the nanosheets.[15] However, the effect of pH 
on the release rate of DOX from graphene sheets was not sig-
nificant. This is an advantage for this system, because it results 
in a minimum leaking of drugs in the cytoplasm, optimum 
nucleus localization, and laser-triggered release of DOX. These 
spatiotemporally controlled release properties are very helpful 
for precise tumor therapy and to mitigate the unwanted side 
effects.[49,50]
2.4. DOX Cellular Uptake and Antitumor Effect
GOPD and GOPRD were incubated with HeLa-R cells for 12 h 
to investigate the intracellular DOX release and distribution. 
The cells were irradiated with NIR laser (808 nm, 0.5 W cm−2) 
for 10  min after 6 h incubation and non-irradiated cells were 
used as control. For the DOX.HCl-incubated HeLa-R cells, a 
significant difference between the irradiated and non-irradiated 
cells was not observed (Figure 5A). In both cases, the amount 
of DOX inside the cells and its therapeutic effect against cancer 
cells was low. The half maximal inhibitory concentration (IC50) 
value for DOX.HCl against HeLa-R cells with and without 
laser irradiation was 18.6 and 20.9  µg mL−1, respectively 
(Figure  5C,D). The resistance of HeLa-R cells against DOX 
is due to many factors, especially overexpressed P-gP on the 
plasma membrane as efflux pumps.[14,15]
The DOX signal in GOPD-treated cells, before and after 
laser irradiation, was similar to free DOX (Figure  5A). The 
reason for weak DOX signal is either low uptake of this drug 
or the lack of targeting ligand in GOPD and localization in 
the cytoplasm, where most of the released DOX molecules 
were “pumped” into the external cellular environment. 
However, the IC50 value for the cells incubated with GOPD 
Figure 4. In vitro release profiles of DOX from the A) GOPD and B) GOPRD at 37 °C under various conditions. NIR laser irradiation (808 nm, 0.5 W cm−2) 
was applied 5 min every 1 h. Mean ± SD (n = 3).
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reduced from 50.1 to 12.3  µg mL−1 after laser irradiation 
(Figure  5C,D). The enhanced therapeutic effect was attrib-
uted to the photothermal effect of nGO sheets and promoted 
release of therapeutic agents. Laser irradiation of cells treated 
with GOPRD resulted in a high DOX signal in nucleus, indi-
cating the efficient nucleus translocation by cR10 peptide 
(Figure 5A). Before irradiation, the signal of DOX was weak, 
because its fluorescence was partially quenched by nGO 
sheets (Figure S9, Supporting Information).[15,44] This result 
confirmed that DOX molecules were majorly associated 
with nGO, and they were not considerably released during 
their journey inside the cytoplasm. The low IC50 of GOPRD 
without laser irradiation (9.4  µg mL−1) is another proof for 
the successful targeting of this carrier and associating cargo 
with the carrier until nucleus internalization (Figure 5C). The 
IC50 of GOPRD plummeted to 1.1 µg mL−1 when NIR laser 
was employed. The high DOX content of the GOPRD-treated 
cells (Figure  5B) and high therapeutic effect of this carrier 
(Figure 5D) proved the incapacity of MDR cells to discharge 
released DOX molecules into the external cellular environ-
ment after nuclear localization. From the in vitro studies, 
it can be concluded that the cR10-functionalized graphene 
sheets were able to efficiently circumvent the MDR, due to 
the combination of a series of unique physicochemical and 
biological properties.
2.5. Biodistribution and Photothermal Effect
Although promising therapeutic effects were obtained in vitro, 
they cannot afford an efficient nGO-based nucleus-targeting 
and anticancer ability in vivo. However, the hPG coverage 
of the sheets decreases their unspecific interactions with 
the biosystems and effectively relieves the possible inju-
ries,[15] which was reported for the bare graphene-treated ani-
mals.[51] Nanocarriers were labeled with 1,1′-bis(4-sulfobutyl)
indodicarbocyanine-5-carboxylic acid (IDCC, a derivative dye 
of Cy5), and their biodistribution was studied. The labeled 
carriers were injected into the HeLa-R tumor-bearing nude 
mice. Mice were sacrificed after 24 h, and their tumors 
and main organs were isolated. The fluorescence intensi-
ties were measured quantitatively (Figure  6B and Table S3, 
Supporting Information). The fluorescence signal in tumors 
was stronger than other organs, such as liver and kidney, 
confirming an effective tumor localization of carriers. 
Interestingly, the accumulation of GOPR in tumors and 
organs was higher than GOP, which may have been attrib-
uted to the higher cellular internalization efficacy of this 
system.
In addition to triggering the release of the cargo, laser can 
induce a photothermal effect of nGO sheets, which improved 
the anticancer efficacy of these systems synergically.[8] In order 
to investigate the photothermal effect of carriers, saline, DOX.
HCl, GOPD, and GOPRD were intravenously administrated 
into nude mice. After 24 h, the NIR laser (808 nm, 0.5 W cm−2) 
irradiation was applied in the tumor sites, and tumor local 
temperature was monitored with a thermal camera. While 
the tumor temperature of the saline- and DOX.HCl-treated 
mice increased from 30 to 37  °C, it reached 44.9 and 48.6  °C 
for GOPD- and GOPRD-treated mice, respectively (Figure  6A). 
This temperature range is reported to show an effective photo-
thermal effect.[7,8]
Figure 5. A) CLSM images of HeLa-R cells after 12 h incubation with DOX.HCl, GOPD, and GOPRD. For the experiments in the second row, cells were 
irradiated by NIR laser (808 nm, 0.5 W cm−2) for 10 min after 6 h incubation. Scale bars correspond to 50 µm. B) FACS results for HeLa-R cells incubated 
with DOX.HCl, GOPD, and GOPRD after 12 h. NIR laser (808 nm, 0.5 W cm−2) irradiation was performed for 10 min after 6 h incubation. Anticancer 
efficacy of DOX.HCl, GOPD, and GOPRD after 24 h incubation with HeLa-R cells C) without and D) with laser irradiation. Cells were irradiated by NIR 
laser (808 nm, 0.5 W cm−2) for 10 min after 6 h incubation. Mean ± SD (n = 3).
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2.6. In Vivo Anticancer Effect
The tumor size (Figure 6C) and body weight (Figure S12, Sup-
porting Information) were recorded in the following 16 days 
after treatment. The tumors of saline- and DOX.HCl-treated 
mice grew very fast, and DOX.HCl alone only exhibited lim-
ited tumor suppression. In the case of GOPD-treated mice, 
the antitumor efficacy slightly improved but still was far away 
from satisfaction, even with irradiation. This was due to the low 
uptake efficacy and intra-cytoplasm release of drug, as well as 
its moderate photothermal effect. However, GOPRD showed 
much higher antitumor efficacy even without laser irradiation, 
and the tumor size was only 32.4% compared with the DOX.
HCl-treated mice. This could be attributed to the efficient cR10 
targeting and intra-nucleus release of the loaded DOX mole-
cules. The most exciting therapeutic results came from the 
combination of GOPRD and laser irradiation at the tumor sites. 
The tumors kept shrinking during the whole treatment (the 
tumor size was only 10.1% compared with the DOX.HCl-treated 
mice after the therapy), which indicated the rational strategy to 
conquer MDR tumors.
The adverse side effects, including hair loss, bone marrow 
suppression, inflammation of the mouth, and other things, 
are always the concern of DOX when it is applied for clinical 
patients.[52] Body weight as the most representative indicator, 
was recorded to analyze the side effects of GOPRD (Figure S12, 
Supporting Information). It could be seen that the weight loss 
for the DOX.HCl-injected mice was quite apparent, particu-
larly in the initial treatment stage. In addition, obvious dis-
eased regions could be found in the heart histological staining 
of DOX.HCl-treated mice, indicating its serious cardiotoxicity 
(Figure S13, Supporting Information). These side effects could 
Figure 6. A) Thermographic images of HeLa-R tumor-engrafted nude mice after treatment with saline, DOX.HCl, GOPD, and GOPRD. The tumors were 
irradiated by NIR laser (808 nm, 0.5 W cm−2) for 10 min. B) Quantitative calculation of in vivo DOX biodistributions in different organs and tumors of 
the nude mice 24 h after intravenous injection. C) The tumor volumes of HeLa-R tumor engrafted nude mice after treatment with saline 1), DOX.HCl 
2), GOPRD 3), GOPR 4), GOPD 5), and GOPRD 6). The tumors of mice in groups 1, 2, 4, 5, and 6 were irradiated with NIR laser (808 nm, 0.5 W cm−2) 
for 10 min. Each nude mouse was intravenously administered at a dose of 5 mg kg−1 (DOX/body weight) at the beginning of this therapy. (*p < 0.0001; 
**p < 0.00001). D) Immunohistochemical analysis for HeLa-R tumors. Positive staining cells in Ki67 and TUNEL analysis are with a brown color. Scale 
bars correspond to 250 µm.
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rarely be observed in the GOPD- and GOPRD-treated mice, con-
firming the low side effects of these nanocarriers.
In order to investigate the antitumor therapeutic mechanism 
of these nucleus-targeting nanosheets, histological staining anal-
yses were applied to the isolated tumors, including hematoxylin 
and eosin (H&E),[53] Ki67,[54] and TUNEL.[55] Compact tumor 
tissue was found for saline- and DOX.HCl-treated mice, while 
a remarkable reduction of tumor cells and more vacancies were 
observed after GOPRD administration (Figure S13, Supporting 
Information). Furthermore, less Ki67-positive cells (proliferative 
cells) and more TUNEL-positive cells (apoptotic cells) could be 
found in the GOPRD-treated tumors (Figure 6D). On contrary, 
more proliferative tumor cells and less apoptotic tumor cells 
were observed in the case of saline- and DOX.HCl-treated mice 
(Figure 6D). These results confirmed the successful antitumor 
therapy by nucleus-targeting graphene-based nanoplatforms.
3. Conclusion
We demonstrated that the MDR in cancer could be successfully 
bypassed both in vitro and in vivo by nucleus targeting poly-
glycerol-covered graphene nanosheets. The effectivity of these 
systems to incapacitate MDR was due to the successful com-
bination of different aspects, including high ability of cR10 for 
nucleus targeting, strong association of DOX with nGO sheets, 
and a laser-triggered release of DOX and photothermal effect. 
GOPRD with and without laser irradiation showed the best 
and second best results, pointing out the critical role of cR10 to 
circumvent the MDR effect. An abrupt increase in the signal of 
nucleus-localized DOX and synergic photothermal and chemo-
therapy upon laser irradiation was a solid proof for the asso-
ciation of cargo and carriers even after nucleus internalization. 
This work introduced a newly developed, cyclic peptide-directed 
nucleus-translocation nanomedicine and opens a new gate to 
conquer MDR tumors in the future.
4. Experimental Section
Preparation of DOX-Loaded GOP and GOPR: Hydrophobic DOX was 
prepared based on the reported protocol.[44] GOP (20 mg) was dispersed 
in PBS (7.4, 20 mL), and then DOX (10 mg) dissolved in DMSO (1 mL), 
was added to this dispersion dropwise. The mixture was stirred overnight 
at room temperature and then centrifuged at 2000 rpm for 10 min. The 
supernatant was collected, and GOPD was obtained after lyophilization. 
GOPRD was prepared with the same procedure.
The DOX loading capacity in GOPD and GOPRD was measured by 
absorption at 545  nm and based on the standard curve (Figure S8, 
Supporting Information), which was calculated from DOX solutions 
(1–5  µg mL−1). The following equation was employed to calculate the 
drug-loading capacity (DLC):
DLC =
mass of DOX innanocarriers




Release Profile of GOPD and GOPRD: GOPD with 80 µg DOX content 
was dispersed in PBS (4 mL, pH 7.4), and then it was equally transferred 
into four dialysis tubes (spectra/Por MWCO 2 kD). Afterward, the tubes 
were immersed in four vials (2 vials contained 30 mL PBS with pH 7.4, 
while the other 2 vials contained 30 mL PBS with pH 5.6). Vials were set 
up in a thermostatic water bath (37  °C) on a heating rotator. Samples 
(0.1  mL) from vial medium were used for fluorescence measurements 
at 1 h intervals, and meanwhile, fresh PBS (0.1  mL) was replenished. 
One of the vials at each pH (pH 7.4 and 5.6) was irradiated with NIR 
laser (808  nm, 0.5 W cm−2) for 5  min every 1 h. The concentration of 
released DOX at different time frames was determined by a microplate 
reader with excitation at 480 nm and emission at 550 nm, and using the 
calibration curve. The drug release studies were performed in triplicate. 
The release profiles of GOPRD were measured by the same way.
Cell Culture: All cell experiments were performed according to the 
German genetic engineering law and German biosafety guidelines in 
laboratory (level 1 biosafety). Dulbecco’s modified eagle’s medium 
(DMEM) and fetal bovine serum (FBS) were used for experiments. 
Multidrug-resistant human cervical tumor cells (HeLa-R cells) were 
received from Leibnitz Institute DSMZ—German Collection of 
Microorganisms and Cell Cultures. HeLa-R cells were cultured in DMEM 
supplemented with 10% (v/v) FBS and 1% penicillin-streptomycin at 
37  °C with 5% CO2 in a humidified atmosphere. Additionally, DOX.
HCl (0.5 µg mL−1) was added in the medium during the incubation to 
maintain their drug-resistance.
CCK-8 Assay: HeLa-R cells (5 × 103 cells per well) were seeded in 
96-well plates with 100 µL DMEM and cultured for another 24 h before 
the biocompatibility and antitumor tests.
GOP and GOPR were dissolved in the culture medium and then 
added to the HeLa-R cell with a series of concentrations (from 1 to 
500  µg mL−1), respectively. The culture medium solutions were 
removed after 24 h incubation, and the wells were rinsed with PBS. 
Afterward, medium-containing CCK-8 (100 µL, 10%) was added to each 
well. After a 2 h incubation, the absorbance of each well at 450  nm 
was measured. Cells without any treatments were considered as a 
negative control, and the cytotoxicity of DOX.HCl (2 and 50 µg mL−1) 
was measured in the same way as the positive controls. Each test was 
triplicated.
The antitumor tests for GOPD and GOPRD were performed by almost 
the same procedure. However, the concentration of DOX was changed 
from 0.01 to 100 µg mL−1. The tests were replicated as 2 groups, and NIR 
laser irradiation (808 nm, 0.5 W cm−2) was employed to one group for 
10 min after 6 h incubation.
Confocal Laser Scanning Microscopy: HeLa-R cells were seeded in 
8-well plates with the density of 3 × 104 cells per well and incubated 
for another 24 h before CLSM experiments. Cellular uptake of GOP 
and GOPR: GOPF and GOPRF were dispersed in DMEM (20 µg mL−1) 
and incubated with the cells at 37  °C for 1, 3, and 6 h, respectively. 
Subsequently, the wells were rinsed with PBS, and then the nucleus of 
HeLa-R cells was stained with Hoechst for 30 min. Afterward, cells were 
observed with CLSM (Leica TCS SP8). Hoechst was excited at 350 nm 
with the emission at 460 nm, and FITC was excited at 488 nm with the 
emission at 520  nm. Intracellular DOX release: DOX.HCl, GOPD, and 
GOPRD were dispersed in DMEM and then added to the wells. The 
concentration of DOX for all experiments was set at 5 µg mL−1. Each 
experiment was replicated as two groups, and the cell culture medium 
was refreshed after 6 h incubation. Subsequently, one group was treated 
with NIR laser irradiation (808  nm, 0.5 W cm−2) for 10  min, while 
the other group was not treated and used as control. Afterward, the 
cells were incubated with the fresh medium for additional 6 h. Finally, 
cells were rinsed with PBS and the nucleus was stained with Hoechst 
before evaluation by CLSM. Hoechst was excited at 350  nm with the 
emission at 460 nm, and DOX was excited at 488 nm with the emission 
at 550 nm.
Flow Cytometer: HeLa-R cells were seeded in 24-well plates (5 × 104 
cells per well), and they were incubated for 24 h before experiments. 
Cellular uptake of GOP and GOPR: GOPF and GOPRF were dispersed 
in DMEM (20  µg mL−1) and then added to the cells. The cells were 
incubated with GOPF and GOPRF for 6 h before rinsing with PBS. Then 
the cells were treated with trypsin/EDTA for 4  min and centrifuged at 
1000 rpm, and the supernatant was discarded. Cells were re-suspended 
in PBS, and fluorescence was measured (excitation: 488 nm; emission: 
520  nm) using a BD FACS caliber flow cytometer. Intracellular DOX 
release: DOX.HCl, GOPD, and GOPRD were dispersed in DMEM and 
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then added to the cells. The concentration of DOX for all experiments 
was set at 5 µg mL−1, and all of the experiments were replicated as two 
groups. One group was treated with NIR laser irradiation (808  nm, 
0.5 W cm−2) for 10 min after 6 h incubation while the other group was 
not treated and used as control. Afterward, the cells were incubated 
with fresh medium for another 6 h before rinsing with PBS. Then the 
cells were treated with trypsin/EDTA and centrifuged to discard the 
supernatant. Cells were re-suspended in PBS, and fluorescence was 
measured (excitation: 488  nm; emission: 550  nm) using a BD FACS 
caliber flow cytometer.
Tumor Xenograft Models on Nude Mice: Female BALB/c nude mice 
(4 weeks old) were purchased from Model Animal Research Center of 
Nanjing University (Nanjing, China), and all animal experiments were 
conducted in compliance with the National Institute of Health Guide for 
the Care and Use of Laboratory Animals (China). 1 × 106 HeLa-R cells 
were subcutaneously inoculated into the right flank of one nude mouse 
to construct the tumor-bearing mice. Tumor size was measured by 
electronic caliper, and the tumor volume (V) was calculated as V = a2 × 
b/2 (a and b represent the width and length of the tumor, respectively). 
And the body weight of nude mice was recorded by an electronic 
balance.
In Vivo Photothermal Studies: HeLa-R tumor-bearing nude mice 
were intravenously injected with saline, DOX.HCl, GOPD, and GOPRD 
(5  mg kg−1). After 24 h, the tumor sites were irradiated by NIR laser 
(808 nm, 0.5 W cm−2) for 10 min, and the thermal photos were recorded 
by an IR thermal imaging camera (FLIR, E40) during the irradiation every 
2 min.
In Vivo Biodistribution Studies: For the quantitative drug distribution 
experiments, HeLa-R tumor-bearing nude mice were intravenously 
administrated with GOPD and GOPRD (5 mg kg−1). After 24 h, the mice 
were sacrificed, and the organs were extracted and homogenized in 
1  mL 1% Triton X-100. Extracting solution (HCl-IPA, 5  mL) was added 
to tissue lysates and the samples were kept at 4 °C overnight. After that, 
the mixture was centrifuged at 11000 rpm for 15 min. The concentration 
of DOX was determined by the fluorescence measurement of the 
supernatant.
In Vivo Antitumor Efficacy: When the tumor volume reached about 
100 mm3, the nude mice were randomly divided into 6 groups with 
6 mice in one group. Then the mice were intravenously administrated 
with saline (group 1), DOX.HCl (group 2), GOPRD (group 3), GOPR 
(group 4), GOPD (group 5), and GOPRD (group 6). The ratio of DOX 
amount and body weight was 5 mg kg−1. After 24 h, the tumors in groups 
1, 2, 4, 5, and 6 were irradiated with NIR laser (808  nm, 0.5 W cm−2) 
for 10 min. The tumor size and body weight were recorded every 2 days 
during the treatment. The mice were sacrificed after 16 days, and then 
the tumors and major organs were isolated and stained by hematoxylin 
& eosin (H&E). In addition, Ki67 and TUNEL immunostaining were also 
applied for all of the tumors.
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